0001209191-19-053286.txt : 20191016
0001209191-19-053286.hdr.sgml : 20191016
20191016162023
ACCESSION NUMBER: 0001209191-19-053286
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191014
FILED AS OF DATE: 20191016
DATE AS OF CHANGE: 20191016
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lloyd-Smith Malcolm
CENTRAL INDEX KEY: 0001557146
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 191152965
MAIL ADDRESS:
STREET 1: 12481 HIGH BLUFF DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-10-14
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001557146
Lloyd-Smith Malcolm
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Regulatory Officer
Common Stock
2019-10-14
4
M
0
9956
15.45
A
29569
D
Common Stock
2019-10-14
4
S
0
9956
90.8484
D
19613
D
Non-Qualified Stock Option
15.45
2019-10-14
4
M
0
9956
15.45
D
2024-10-01
Common Stock
9956
0
D
Includes a total of 375 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan. 190 shares were purchased on February 28, 2019 and 185 shares were purchased on August 30, 2019.
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $90.05 to $91.70 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Option granted October 1, 2014 and vested at 25% upon first anniversary (October 1, 2015) and remaining 75% vested in 36 equal monthly installments beginning November 1, 2015.
/s/ Darin Lippoldt, Attorney-in-Fact
2019-10-16